Professor Erika Lietzan was quoted at length today in an article published by the Regulatory Affairs Professional Society (RAPS) about the impact of President Trump’s January 30 “two-for-one” executive order on the U.S. Food and Drug Administration (FDA). The executive order provides that whenever an agency promulgates a new regulation, it must identify at least two existing regulations to be…